Antimicrobial Agents Practice Questions

Q: What is the drug of choice for chronic hepatitis B?

Lamivudine. **Explanation:** **Correct Option: A (Lamivudine)** Lamivudine is a nucleoside analog that inhibits the Hepatitis B virus (HBV) DNA polymerase (reverse transcriptase). In the context of this specific question, Lamivudine is historically recognized as the first-line oral antiviral for chronic Hepatitis B due to its high efficacy in suppressing HBV DNA levels and its favorable safety profile compared to older therapies. While newer agents like Tenofovir and Entecavir are now preferred in modern guidelines due to lower resistance rates, Lamivudine remains the classic "textbook" answer for NEET-PG when listed among these specific options. **Incorrect Options:** * **B. Interferon-alpha:** While used in chronic HBV, it is administered via injection and carries a significant side-effect profile (flu-like symptoms, depression, bone marrow suppression), making it less preferred than oral antivirals for long-term management. * **C. Ribavirin:** This is used primarily for **Hepatitis C** (in combination with Interferon or DAAs) and has no significant clinical activity against Hepatitis B. * **D. Zidovudine (AZT):** This is a nucleoside reverse transcriptase inhibitor (NRTI) used exclusively for **HIV**; it does not have a role in treating Hepatitis B. **High-Yield Clinical Pearls for NEET-PG:** * **Current Gold Standard:** In clinical practice, **Tenofovir** or **Entecavir** are the drugs of choice due to a high genetic barrier to resistance. * **Resistance:** The major drawback of Lamivudine is the development of resistance (YMDD motif mutation). * **Pregnancy:** Tenofovir is the preferred agent to prevent mother-to-child transmission of HBV. * **Adefovir:** Another alternative, but limited by potential nephrotoxicity.

Q: Which of the following is the drug of choice for Campylobacter jejuni infection?

Erythromycin. **Explanation:** *Campylobacter jejuni* is one of the most common causes of bacterial gastroenteritis worldwide, typically presenting as inflammatory diarrhea (bloody stools), fever, and abdominal cramps. **1. Why Erythromycin is the Correct Answer:** Macrolides are the mainstay of treatment for *Campylobacter* enteritis. While many modern guidelines mention Azithromycin due to its convenient once-daily dosing, **Erythromycin** remains the classic "Drug of Choice" (DOC) cited in standard pharmacology textbooks (like K.D. Tripathi) and frequently tested in NEET-PG. It effectively shortens the duration of pathogen excretion and reduces the severity of symptoms if administered early. **2. Why Other Options are Incorrect:** * **Azithromycin (Option A):** While clinically effective and often preferred in practice due to better GI tolerance, Erythromycin is traditionally established as the gold standard in academic examinations for this specific organism. * **Metronidazole (Option B):** This is the DOC for anaerobic infections and protozoal diseases like Amoebiasis or Giardiasis. It has no activity against *Campylobacter*. * **Ampicillin (Option C):** *Campylobacter* species show high rates of resistance to penicillins; therefore, they are not used for empirical or definitive treatment. **3. High-Yield Clinical Pearls for NEET-PG:** * **Morphology:** *C. jejuni* is a Gram-negative, comma or S-shaped organism ("seagull wing" appearance) that is microaerophilic and grows best at 42°C (Skirrow’s medium). * **Complication:** It is the most common antecedent infection associated with **Guillain-Barré Syndrome (GBS)** due to molecular mimicry. * **Resistance Trend:** Fluoroquinolones (like Ciprofloxacin) were previously used but are now avoided due to rapidly rising resistance. * **Treatment Note:** Most cases are self-limiting and require only oral rehydration; antibiotics are reserved for severe or prolonged cases.

Q: Nalidixic acid is used in:

Urinary tract infections (UTI). **Explanation:** **Nalidixic acid** is the prototype of the first-generation **Quinolones**. Its clinical utility is primarily restricted to **Urinary Tract Infections (UTIs)** because it achieves high therapeutic concentrations in the urine but fails to reach effective systemic antibacterial levels in the blood or tissues. 1. **Why Option A is Correct:** Nalidixic acid is a narrow-spectrum urinary antiseptic. It is bactericidal against gram-negative organisms (like *E. coli, Proteus, Klebsiella*) by inhibiting the **DNA gyrase** enzyme. Following oral administration, it is rapidly absorbed but also rapidly excreted in the urine, making it effective for lower UTIs caused by susceptible strains. 2. **Why Other Options are Incorrect:** * **B & C (Bacillary Dysentery/Enteric Fever):** While Nalidixic acid has *in vitro* activity against some enteric pathogens, its poor systemic distribution and the rapid development of bacterial resistance make it unsuitable for systemic infections like typhoid (Enteric fever) or severe dysentery. Fluoroquinolones (e.g., Ciprofloxacin) are preferred for these conditions. * **D (Malaria):** Quinolones are antibacterial agents, not antimalarials. Malaria is caused by *Plasmodium* parasites and requires drugs like Chloroquine or Artemisinin-based combinations. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Inhibits DNA gyrase (Topoisomerase II) in gram-negative bacteria. * **Resistance:** Resistance develops rapidly during treatment via chromosomal mutations (single-step mutation). * **Contraindication:** It should be avoided in patients with **G6PD deficiency** as it can precipitate hemolysis. * **Side Effects:** Common side effects include GI upset and CNS effects (headache, dizziness). It is generally avoided in children due to potential **cartilage toxicity** (a class effect of quinolones).

Q: What is the mechanism of action of maraviroc?

CCR5 inhibitor. Explanation: Mechanism of Action: Maraviroc is a unique antiretroviral agent classified as an Entry Inhibitor. For HIV to enter a host cell, the viral envelope protein gp120 must bind to the CD4 receptor and subsequently to a co-receptor, either CCR5 or CXCR4 [1]. Maraviroc selectively and reversibly binds to the CCR5 co-receptor on the surface of human CD4+ T-cells [1]. This binding induces a conformational change that prevents the viral gp120 from docking, thereby blocking the fusion and entry of "R5-tropic" HIV strains into the host cell [1], [4]. Analysis of Incorrect Options: * Option A (Cytochrome P450 inhibitor): While Maraviroc is a substrate of CYP3A4, it is not primarily used as an inhibitor [3]. Ritonavir is the classic example of a protease inhibitor used specifically for its CYP3A4 inhibitory effect ("boosting"). * Option B (GP 41 inhibitor): Enfuvirtide is the drug that targets gp41 [2]. It prevents the fusion of the viral envelope with the host cell membrane. * Option D (GP 120 inhibitor): Fostemsavir is a newer attachment inhibitor that binds directly to the viral gp120 protein to prevent initial attachment to CD4 cells. High-Yield Clinical Pearls for NEET-PG: * Tropism Testing: Before initiating Maraviroc, a Trofile assay must be performed. It is only effective against R5-tropic virus and is ineffective against X4-tropic or dual-tropic (R5X4) strains [1], [3]. * Metabolism: It is metabolized by CYP3A4; therefore, dosage adjustments are required when co-administered with CYP inhibitors (like protease inhibitors) or inducers (like Rifampin) [1], [3]. * Black Box Warning: Potential for hepatotoxicity which may be preceded by systemic allergic reactions (eosinophilia/rash) [3].

Q: What is the standard oral dose of oseltamivir for treatment?

75 mg twice daily for 5 days orally. **Explanation:** **Oseltamivir** is a neuraminidase inhibitor used for the treatment and prophylaxis of Influenza A and B. It works by preventing the release of new viral particles from infected host cells. **1. Why Option A is Correct:** The standard therapeutic dose for adults and adolescents (weighing >40 kg) is **75 mg twice daily (BID) for 5 days**. For the drug to be most effective, it must be initiated within **48 hours** of the onset of symptoms. It is administered **orally** as a prodrug (oseltamivir phosphate), which is rapidly converted by hepatic esterases into its active form, oseltamivir carboxylate. **2. Why Other Options are Incorrect:** * **Options B & D:** Oseltamivir is specifically an **oral** medication. If intravenous neuraminidase inhibition is required (e.g., in critically ill patients unable to tolerate oral meds), **Peramivir** is the drug of choice. * **Option C:** 200 mg is not a standard dose. Higher doses (e.g., 150 mg BID) have been studied for severe infections (H5N1) or immunocompromised patients, but 75 mg BID remains the gold standard for seasonal influenza. **High-Yield Clinical Pearls for NEET-PG:** * **Prophylaxis Dose:** 75 mg **once daily** for 7–10 days (post-exposure) or up to 6 weeks (during community outbreaks). * **Mechanism:** Competitive inhibition of **Neuraminidase**, preventing viral shedding. * **Pregnancy:** Oseltamivir is the preferred antiviral for pregnant women with influenza. * **Side Effects:** Most common are GI upset (nausea/vomiting); rare but serious neuropsychiatric events (confusion, self-injury) have been reported in children. * **Zanamivir:** An alternative neuraminidase inhibitor administered via **inhalation** (contraindicated in asthma/COPD due to risk of bronchospasm).

Q: What is the most important side effect of Amphotericin B?

Nephrotoxicity. **Explanation:** **Amphotericin B** is a potent polyene antifungal used for systemic fungal infections. While it has several adverse effects, **Nephrotoxicity** is the most significant and dose-limiting side effect. **1. Why Nephrotoxicity is the Correct Answer:** Amphotericin B works by binding to ergosterol in fungal cell membranes to create pores. However, it also has a partial affinity for **cholesterol** in human renal tubular cells. This leads to: * **Direct Toxicity:** Damage to the renal tubular epithelium, causing electrolyte wasting (Type 1 RTA). * **Indirect Toxicity:** Vasoconstriction of the afferent arterioles, leading to decreased Renal Blood Flow (RBF) and Glomerular Filtration Rate (GFR). This "azotemia" occurs in nearly 80% of patients treated with the conventional deoxycholate form. **2. Analysis of Incorrect Options:** * **A. Fever and Chills:** These are common **infusion-related reactions** (the "shake and bake" phenomenon). While frequent, they are transient and manageable with premedication (NSAIDs/steroids), unlike the cumulative damage of nephrotoxicity. * **C. Hyperkalemia:** This is incorrect because Amphotericin B typically causes **Hypokalemia** and **Hypomagnesemia** due to increased distal tubular permeability and wasting. * **D. Anemia:** It causes a normocytic normochromic anemia due to decreased erythropoietin production by the damaged kidneys, but it is secondary to the renal impact. **High-Yield Clinical Pearls for NEET-PG:** * **Liposomal Amphotericin B:** Developed to reduce nephrotoxicity by targeting the drug specifically to fungal cells and avoiding the kidneys. * **Saline Loading:** Administering 1 liter of normal saline before the infusion is the standard clinical practice to minimize nephrotoxicity. * **Drug of Choice:** Despite its toxicity, it remains the gold standard for **Mucormycosis** and severe **Visceral Leishmaniasis**.

Q: Roxithromycin is:

A long acting macrolide. **Explanation:** **Roxithromycin** is a semi-synthetic **macrolide antibiotic** derived from Erythromycin. It is categorized as a **long-acting macrolide** primarily due to its superior pharmacokinetic profile compared to the prototype drug, Erythromycin. 1. **Why Option A is Correct:** Roxithromycin possesses a significantly longer elimination half-life (approx. **10–12 hours**) compared to Erythromycin (approx. 1.5 hours). This allows for convenient **twice-daily (BD) dosing**, improving patient compliance. It is more acid-stable, has better oral bioavailability, and achieves higher tissue concentrations. 2. **Why Other Options are Incorrect:** * **Option B & C:** Roxithromycin belongs to the macrolide class (characterized by a large lactone ring), not quinolones (e.g., Ciprofloxacin). It is considered "long-acting" relative to the older generation of macrolides. * **Option D:** Polypeptide antibiotics (e.g., Polymyxin B, Bacitracin) have a completely different chemical structure and mechanism of action (disrupting cell membranes). **High-Yield NEET-PG Pearls:** * **Mechanism of Action:** Like all macrolides, it inhibits bacterial protein synthesis by binding to the **50S ribosomal subunit**. * **Spectrum:** Similar to Erythromycin but more potent against *Legionella pneumophila*. * **Drug Interactions:** Roxithromycin has a **lower affinity for Cytochrome P450** enzymes compared to Erythromycin and Clarithromycin, resulting in fewer drug-drug interactions (e.g., with Theophylline or Warfarin). * **Clinical Use:** Commonly used for respiratory tract infections, ENT infections, and skin/soft tissue infections. * **Comparison:** While Roxithromycin is long-acting, **Azithromycin** remains the macrolide with the longest half-life (~68 hours), allowing for once-daily dosing.

Q: According to the recent classification of antitubercular drugs, which of the following drugs is classified under Group II?

Streptomycin. The classification of antitubercular drugs has been updated by the WHO to prioritize oral regimens and optimize the treatment of Drug-Resistant TB (DR-TB). **Explanation of the Correct Answer:** **Streptomycin** is classified under **Group II** (Second-line Injectable Agents). Historically, this group included Kanamycin, Capreomycin, and Amikacin. However, in the most recent WHO guidelines, Streptomycin remains the representative injectable for this category, though its use is declining in favor of all-oral regimens. **Analysis of Incorrect Options:** * **Ethambutol (Option A):** This is a **Group I** drug (First-line oral agents). Group I includes the primary "HRZE" regimen (Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol). * **Levofloxacin (Option B):** This belongs to **Group A** (Fluoroquinolones) in the newer MDR-TB classification. Fluoroquinolones (Levofloxacin, Moxifloxacin) are now considered the most important components of MDR-TB treatment. * **Imipenem (Option D):** This is classified under **Group III** (or Group C in newer nomenclature), which consists of "Add-on agents" or "Other second-line agents" like Linezolid, Clofazimine, and Carbapenems. **NEET-PG High-Yield Pearls:** * **New WHO MDR-TB Classification:** * **Group A:** Fluoroquinolones (Levofloxacin, Moxifloxacin). * **Group B:** Second-line oral agents (Clofazimine, Cycloserine). * **Group C:** Add-on agents (Ethionamide, Linezolid, Bedaquiline, Delamanid). * **Bedaquiline:** Inhibits mycobacterial ATP synthase; it is a breakthrough drug for MDR-TB. * **Streptomycin Side Effect:** Ototoxicity (vestibular damage) and nephrotoxicity; it is contraindicated in pregnancy.

Q: Which of the following antibiotics can cause diabetes insipidus?

Demeclocycline. **Explanation:** **Demeclocycline** is a tetracycline derivative that acts as a specific antagonist to **Antidiuretic Hormone (ADH)** at the level of the renal collecting ducts. It inhibits the activation of adenylyl cyclase and the subsequent action of cAMP, rendering the kidneys unresponsive to ADH. This induced state of **nephrogenic diabetes insipidus** is actually utilized therapeutically to treat **SIADH** (Syndrome of Inappropriate ADH secretion)

Question 1

During treatment with rifampicin, some patients experience mild elevation in bilirubin with normal transaminases. What is the cause of this phenomenon?

Accepted Answer

Hepatic adaptation

Answer

Hemolysis

Answer

Transient cholestasis with bile duct injury

Answer

Microsomal enzyme induction

Question 2

What is the drug of choice for chronic hepatitis B?

Accepted Answer

Lamivudine

Answer

Interferon-alpha

Answer

Ribavirin

Answer

Zidovudine

Question 3

Which of the following is the drug of choice for Campylobacter jejuni infection?

Accepted Answer

Erythromycin

Answer

Azithromycin

Answer

Metronidazole

Answer

Ampicillin

Question 4

Nalidixic acid is used in:

Accepted Answer

Urinary tract infections (UTI)

Answer

Bacillary dysentery

Answer

Enteric fever

Answer

Malaria

Question 5

What is the mechanism of action of maraviroc?

Accepted Answer

CCR5 inhibitor

Answer

Cytochrome P450 inhibitor

Answer

GP 41 inhibitor

Answer

GP 120 inhibitor

Question 6

What is the standard oral dose of oseltamivir for treatment?

Accepted Answer

75 mg twice daily for 5 days orally

Answer

75 mg twice daily for 5 days intravenously

Answer

200 mg twice daily for 5 days orally

Answer

200 mg twice daily for 5 days intravenously

Question 7

What is the most important side effect of Amphotericin B?

Accepted Answer

Nephrotoxicity

Answer

Fever and chills

Answer

Hyperkalemia

Answer

Anemia

Question 8

Roxithromycin is:

Accepted Answer

A long acting macrolide

Answer

A short action quinolone

Answer

A short acting macrolide

Answer

A long acting polypeptide

Question 9

According to the recent classification of antitubercular drugs, which of the following drugs is classified under Group II?

Accepted Answer

Streptomycin

Answer

Ethambutol

Answer

Levofloxacin

Answer

Imipenem

Question 10

Which of the following antibiotics can cause diabetes insipidus?

Accepted Answer

Demeclocycline

Answer

Chloramphenicol

Answer

Minocycline

Answer

Linezolid

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?